Deal Announcements

Orexigen Therapeutics Closes $30 Million Series C

Wednesday, November 22, 2006 8:00:00 AM PDT | VentureDeal Staff

SAN DIEGO, CA --  Orexigen, a clinical-stage neuroscience company, announced the completion of its third round of funding in the amount of $30 million. 

New investors MPM BioEquities and Wasatch Advisors joined all existing investors in the new round.

Orexigen, is developing two new drugs to treat obesity and is currently in phase II/III clinical testing.  The company also has other drugs in earlier stages of testing.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1